|
Year : 2022 |
Volume: 5 |
Issue Number: 3
CORRIGENDUM
Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study
|
| No one has added comments on this article. Click here to add your remarks |
|
Reader
Comments